177Lu-RAD204

N/A

Report date: 2026/02/12 20:00:14

Base Information

Drug Name177Lu-RAD204
Drug Alias NameRAD-204177Lu-RAD204177Lu-anti-PD-L1 sdAb
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Radiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177Lu +[4] 
Mechanisms of ActionIonising radiation emittersAnti-Programmed death-ligand 1
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsSkin MelanomaMismatch Repair Deficient CancerEndometrial Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesRadiopharm Theranostics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRadiopharm Theranostics Ltd
Inactive CompaniesN/A
Active IndicationsSkin MelanomaMismatch Repair Deficient CancerEndometrial Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A